Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

shutterstock_159488225

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …

News
libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

News
lilly_building_with_american_flag_web

Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

September 15, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …

News
shutter

MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn

September 15, 2020
Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …

News
spotlighton-aprile-cw_covid-19-and-cancer-1-img

Oncology research in the age of COVID-19

September 14, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …

Feature
shutterstock_273326141

Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …

News

AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness

September 9, 2020
Research and Development AstraZeneca, COVID-19, pharma

Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted …

News
shutterstock_512649

Takeda to sell another non-core portfolio for $260 million to Cheplapharm

September 8, 2020
Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …

News
sanofi_hq__boetie_hall_web

Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …

News
janssen_latest_logo_on_sign

Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia

September 7, 2020
Sales and Marketing Europe, Janssen, imbruvica, pharma

The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …

News
shutterstock_95714119

Meta-analysis reinforces efficacy of commercially available steroids in hospitalised COVID-19 patients

September 4, 2020
Medical Communications, Research and Development COVID-19, pharma, steroids

A new meta-analysis of seven studies worldwide investigating the benefit for commercially available steroid therapies in the treatment of COVID-19 …

News
shutterstock_159488225

Akebia Therapeutics’ HIF-PH inhibitor passes efficacy goals in chronic kidney disease without dialysis, but falls short on safety

September 4, 2020
Medical Communications, Research and Development Akebia Therapeutics, kidney disease, pharma, vadadustat

Akebia Therapeutics has pulled back the veil on data from the second of two Phase 3 clinical trials for its …

News

NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression

September 3, 2020
Sales and Marketing Janssen, Spravato, depression, pharma

NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …

News
img_4190-e1376666350337-web

MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme

September 3, 2020
Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma

It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …

News
shutterstock_138095450

Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

September 2, 2020
Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026